**Medical marijuana products under state licenses and FDA-approved cannabis drugs moved to Schedule III in late April 2026 via a Justice Department order tied to a December 2025 executive order directing expedited rulemaking.** A separate administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, 2026, as part of efforts to align federal controls with accepted medical use while preserving trafficking enforcement. Trader sentiment on timing for full rescheduling reflects the compressed post-hearing rulemaking window, potential for administrative law judge recommendations, public comment periods, and possible litigation or further agency review before a final rule takes effect. These steps determine whether completion occurs in the third or fourth quarter of 2026 or later.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$796,429 Vol.
Mar 31, 2026
September 30
49%
December 31
27%
$796,429 Vol.
September 30
$0 Vol.
49%
December 31
$186,858 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Medical marijuana products under state licenses and FDA-approved cannabis drugs moved to Schedule III in late April 2026 via a Justice Department order tied to a December 2025 executive order directing expedited rulemaking.**
A separate administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, 2026, as part of efforts to align federal controls with accepted medical use while preserving trafficking enforcement. Trader sentiment on timing for full rescheduling reflects the compressed post-hearing rulemaking window, potential for administrative law judge recommendations, public comment periods, and possible litigation or further agency review before a final rule takes effect. These steps determine whether completion occurs in the third or fourth quarter of 2026 or later.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$796,429শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Medical marijuana products under state licenses and FDA-approved cannabis drugs moved to Schedule III in late April 2026 via a Justice Department order tied to a December 2025 executive order directing expedited rulemaking.**
A separate administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, 2026, as part of efforts to align federal controls with accepted medical use while preserving trafficking enforcement. Trader sentiment on timing for full rescheduling reflects the compressed post-hearing rulemaking window, potential for administrative law judge recommendations, public comment periods, and possible litigation or further agency review before a final rule takes effect. These steps determine whether completion occurs in the third or fourth quarter of 2026 or later.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$796,429শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Medical marijuana products under state licenses and FDA-approved cannabis drugs moved to Schedule III in late April 2026 via a Justice Department order tied to a December 2025 executive order directing expedited rulemaking.** A separate administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, 2026, as part of efforts to align federal controls with accepted medical use while preserving trafficking enforcement. Trader sentiment on timing for full rescheduling reflects the compressed post-hearing rulemaking window, potential for administrative law judge recommendations, public comment periods, and possible litigation or further agency review before a final rule takes effect. These steps determine whether completion occurs in the third or fourth quarter of 2026 or later.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা